Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on January 9, 2015, regarding a material definitive agreement entered into on that date. The Company is a Delaware corporation headquartered in Beverly Hills, California.
Key Financial Metrics
The filing details a private placement transaction rather than periodic financial performance metrics. Key transaction figures include:
- Aggregate Purchase Price: Approximately $10,000,000.
- Shares Issued: 2,839,045 shares of Common Stock.
- Price Per Share: $3.52.
- Expected Cash Inflow: The Company expects to receive the aggregate purchase price on or about January 13, 2015.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, existing debt, or liquidity ratios as of the reporting date.
Material Changes
The primary material change is the entry into a Share Purchase Agreement with select investors. This transaction represents a significant capital raise intended to increase the Company's cash position upon closing. Additionally, the Company entered into a Registration Rights Agreement, obligating it to file a registration statement for the resale of the shares.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company anticipates closing the transaction and receiving funds by January 13, 2015. A press release regarding the placement was issued on January 12, 2015.
Risks and Contingencies:
- Registration Status: The shares sold in this private placement are unregistered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption.
- Investor Restrictions: Investors represented that they are acquiring shares for investment only and not for resale.
- Future Filings: Full terms of the agreements will be disclosed in an amendment to this report following the receipt of funds.
Investor Verification Checklist
- Verify the actual closing date and receipt of the $10,000,000 purchase price.
- Review the upcoming amendment to this Form 8-K for the full text of the Share Purchase and Registration Rights Agreements.
- Confirm the status of the SEC registration statement for the resale of the 2,839,045 shares.
- Assess the impact of the new share issuance on existing shareholder dilution.